Flash glucose monitoring (FM) was introduced in the UK in 2015. The transformative effects of this technology were limited to those who could afford to self-fund purchase of sensors, meaning uptake was heavily skewed towards the most affluent. A lack of strong evidence of benefit (particularly with respect to lowering HbA1c) hindered NHS funding for the device. Work began to highlight the threat of widening social inequalities in outcomes in Type 1 diabetes (T1D) (related to inequitable access to FM) and contributed to an evidence base for efficacy. This information secured liberal eligibility criteria for FM within the Lothian health board and an educational programme ensured 50% of the T1 population were using NHS-funded FM within six months. Subsequent outcome data have supported the case for rollout across the UK.
Back to the top